- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Designed specifically for preclinical research, ultra high-frequency ultrasound systems enable in vivo viewing and assessment of miniscule targets. When combined with high-resolution molecular imaging, these systems allow researchers to view small-animal anatomical structures and micro-environmental functions in real time, such as beating hearts and growing malignancies.
This breakthrough ultrasound technology allows the world's most prestigious pharmaceutical and biotechnology companies, hospitals, and universities to enhance their research capabilities in areas such as translational research, cardiovascular function and disease, cancer, neurobiology, developmental biology, drug development, phenotypic studies, and genetic research, among others.
One company that has established itself as a leader in preclinical, in vivo imaging is VisualSonics, Inc., a wholly owned subsidiary of clinical ultrasound manufacturer SonoSite, Inc., a Fujifilm company. VisualSonics' Vevo® products line includes high-frequency micro-imaging systems (Vevo® 2100 and 770) and a premier photoacoustic imaging platform, the Vevo LAZR*. The Vevo LAZR* has expanded in vivo nanoparticle imaging and microenvironmental research capabilities by simultaneously collecting and displaying high-resolution micro-ultrasound and photoacoustic signals. These systems have found strong utility in advanced preclinical research resulting in over 700 peer-reviewed publications across the globe.
One area where these technologies show particular promise is translational research. Because translational research connects preclinical research at the bench with clinical outcomes at the patients' bedside, the development of research tools that promise and show direct relevance to imaging and quantification of diseases in humans is critical for today's basic science researchers. As the primary and secondary causes of death globally, cardiovascular disease and cancer represent important basic research and clinical research areas, which can be studied in animal models non-invasively in real-time through the use of high-frequency ultrasound. And, using the company's photoacoustic technology for molecular imaging, cancer can be studied in its earliest stages of progression in animal test subjects.
To introduce in vivo high-frequency ultrasound and photoacoustic imaging to researchers and other potential users, VisualSonics has been offering lab visits with top preclinical researchers using these advanced technologies, as well as free webinar presentations by some of the world's most respected authorities on high-resolution micro-imaging.
To register for upcoming webinars, demonstrations, and laboratory visits—or to learn more about ultra high-frequency ultrasound and molecular imaging systems—go to: VisualSonics.com
For more information, please click here
3080 Yonge Street Suite 6100, Box 66
Toronto, Ontario, Canada
North American Toll Free 1.866.416.4636
Copyright © VisualSonics Inc.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Leti Announces Launch of First European Nanomedicine Characterisation Laboratory: Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval July 1st, 2015
Clues to inner atomic life from subtle light-emission shifts: Hyperfine structure of light absorption by short-lived cadmium atom isotopes reveals characteristics of the nucleus that matter for high precision detection methods July 3rd, 2015